Now that Provenge, the prostate cancer drug from Dendreon (DNDN) got past FDA Phase 3 approval, what's next?
The stock jumped from under $30/share to $40/share from January 2010 to April 2010.
Then yesterday, the good news hit, and the stock closed at $50/share, and pre-market indicators already push it higher, yet.
Showing posts with label How high can DNDN go?. Show all posts
Showing posts with label How high can DNDN go?. Show all posts
Friday, April 30, 2010
Subscribe to:
Posts (Atom)